The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile
Open accessAbstract
Several small-molecule Bruton tyrosine kinase (BTK) inhibitors are in development for B cell malignancies and autoimmune disorders, each characterized by distinct potency and selectivity patterns. Herein we describe the pharmacologic characterization of BTK inhibitor acalabrutinib [compound 1, ACP-196 (4-[8-amino-3-[(2S)-1-but-2-ynoylpyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]-N-(2-pyridyl)benzamide)]. Acalabrutinib possesses a reactive butynamide group that binds covalently to Cys481 in BTK. Relative to the other BTK inhibitors described here, the reduced intrinsic reactivity of acalabrutinib helps to limit inhibition of off-target kinases having cysteine-mediated covalent binding potential. Acalabrutinib demonstrated higher biochemical and cellular selectivity than ibrutinib and spebrutinib (compounds 2 and 3, respectively). Importantly, off-target kinases, such as epidermal growth factor receptor (EGFR) and interleukin 2-inducible T cell kinase (ITK), were not inhibited. Determination of the inhibitory potential of anti-immunoglobulin M–induced CD69 expression in human peripheral blood mononuclear cells and whole blood demonstrated that acalabrutinib is a potent functional BTK inhibitor. In vivo evaluation in mice revealed that acalabrutinib is more potent than ibrutinib and spebrutinib. Preclinical and clinical studies showed that the level and duration of BTK occupancy correlates with in vivo efficacy. Evaluation of the pharmacokinetic properties of acalabrutinib in healthy adult volunteers demonstrated rapid absorption and fast elimination. In these healthy individuals, a single oral dose of 100 mg showed approximately 99% median target coverage at 3 and 12 hours and around 90% at 24 hours in peripheral B cells. In conclusion, acalabrutinib is a BTK inhibitor with key pharmacologic differentiators versus ibrutinib and spebrutinib and is currently being evaluated in clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
Byrd, J. C., Furman, R. R., Coutre, S. E., Flinn, I. W., Burger, J. A., Blum, K. A., Grant, B., Sharman, J. P., Coleman, M., Wierda, W. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215637 · Cited by 2,270
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma
Wang, M. L., Rule, S., Martin, P., Goy, A., Auer, R., Kahl, B. S., Jurczak, W., Advani, R. H., Romaguera, J. E., Williams, M. E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306220 · Cited by 1,685
Honigberg, L. A., Smith, A. M., Sirisawad, M., Verner, E., Loury, D., Chang, B., Li, S., Pan, Z., Thamm, D. H., Miller, R. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004594107 · Cited by 1,561
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
Byrd, J. C., Harrington, B., O’Brien, S., Jones, J. A., Schuh, A., Devereux, S., Chaves, J., Wierda, W. G., Awan, F. T., Brown, J. R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1509981 · Cited by 897
Self-citationDubovsky, J. A., Beckwith, K. A., Natarajan, G., Woyach, J. A., Jaglowski, S., Zhong, Y., Hessler, J. D., Liu, T.-M., Chang, B. Y., Larkin, K. M., et al. (2013) · Blood · doi:10.1182/blood-2013-06-507947 · Cited by 810
Discovery of Selective Irreversible Inhibitors for Bruton’s Tyrosine Kinase
Pan, Z., Scheerens, H., Li, S., Schultz, B. E., Sprengeler, P. A., Burrill, L. C., Mendonca, R. V., Sweeney, M. D., Scott, K. C. K., Grothaus, P. G., et al. (2007) · ChemMedChem · doi:10.1002/cmdc.200600221 · Cited by 674
Byrd, J. C., Furman, R. R., Coutre, S. E., Burger, J. A., Blum, K. A., Coleman, M., Wierda, W. G., Jones, J. A., Zhao, W., Heerema, N. A., et al. (2015) · Blood · doi:10.1182/blood-2014-10-606038 · Cited by 663
X-Linked Agammaglobulinemia: Report on a United States Registry of 201 Patients
Winkelstein, J. A., Marino, M. C., Lederman, H. M., Jones, S. M., Sullivan, K., Burks, A. W., Conley, M. E., Cunningham-Rundles, C., & Ochs, H. D. (2006) · Medicine · doi:10.1097/01.md.0000229482.27398.ad · Cited by 639
Targeting Bruton's tyrosine kinase in B cell malignancies
Hendriks, R. W., Yuvaraj, S., & Kil, L. P. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3702 · Cited by 552
O'Brien, S., Furman, R. R., Coutre, S. E., Sharman, J. P., Burger, J. A., Blum, K. A., Grant, B., Richards, D. A., Coleman, M., Wierda, W. G., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70513-8 · Cited by 466
Self-citationWang, M. L., Blum, K. A., Martin, P., Goy, A., Auer, R., Kahl, B. S., Jurczak, W., Advani, R. H., Romaguera, J. E., Williams, M. E., et al. (2015) · Blood · doi:10.1182/blood-2015-03-635326 · Cited by 410
Lynch, T. J., Kim, E. S., Eaby, B., Garey, J., West, D. P., & Lacouture, M. E. (2007) · The Oncologist · doi:10.1634/theoncologist.12-5-610 · Cited by 341
Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks
Barf, T., & Kaptein, A. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3003203 · Cited by 331
Self-citationUnderstanding, recognizing, and managing toxicities of targeted anticancer therapies
Dy, G. K., & Adjei, A. A. (2013) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21184 · Cited by 331
Kortemme, T., & Creighton, T. E. (1995) · Journal of Molecular Biology · doi:10.1006/jmbi.1995.0592 · Cited by 317
Src family kinases: at the forefront of platelet activation
Senis, Y. A., Mazharian, A., & Mori, J. (2014) · Blood · doi:10.1182/blood-2014-01-453134 · Cited by 296
Ibrutinib‐associated bleeding: pathogenesis, management and risk reduction strategies
Shatzel, J. J., Olson, S. R., Tao, D. L., McCarty, O. J. T., Danilov, A. V., & DeLoughery, T. G. (2017) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13651 · Cited by 279
Walter, H. S., Rule, S. A., Dyer, M. J. S., Karlin, L., Jones, C., Cazin, B., Quittet, P., Shah, N., Hutchinson, C. V., Honda, H., et al. (2016) · Blood · doi:10.1182/blood-2015-08-664086 · Cited by 268
A role for Bruton's tyrosine kinase (Btk) in platelet activation by collagen
Quek, L. S., Bolen, J., & Watson, S. P. (1998) · Current Biology · doi:10.1016/s0960-9822(98)70471-3 · Cited by 253
Evans, E. K., Tester, R., Aslanian, S., Karp, R., Sheets, M., Labenski, M. T., Witowski, S. R., Lounsbury, H., Chaturvedi, P., Mazdiyasni, H., et al. (2013) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.203489 · Cited by 220
Ibrutinib antagonizes rituximab-dependent NK cell–mediated cytotoxicity
Kohrt, H. E., Sagiv-Barfi, I., Rafiq, S., Herman, S. E. M., Butchar, J. P., Cheney, C., Zhang, X., Buggy, J. J., Muthusamy, N., Levy, R., et al. (2014) · Blood · doi:10.1182/blood-2014-01-547869 · Cited by 217
de Weers, M., Verschuren, M. C. M., Kraakman, M. E. M., Mensink, R. G. J., Schuurman, R. K. B., van Dongen, J. J. M., & Hendriks, R. W. (1993) · European Journal of Immunology · doi:10.1002/eji.1830231210 · Cited by 202
Gomez-Rodriguez, J., Wohlfert, E. A., Handon, R., Meylan, F., Wu, J. Z., Anderson, S. M., Kirby, M. R., Belkaid, Y., & Schwartzberg, P. L. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20131459 · Cited by 180
Herman, S. E. M., Montraveta, A., Niemann, C. U., Mora-Jensen, H. I., Gulrajani, M., Krantz, F., Mantel, R., Smith, L. L., McClanahan, F., Harrington, B. K., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0463 · Cited by 172
Self-citationPatel, V. M., Balakrishnan, K., Бибикова, Е., Ayres, M., Keating, M. J., Wierda, W. G., & Gandhi, V. V. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1446 · Cited by 163
Jongstra‐Bilen, J., Cano, A. P., Hasija, M., Xiao, H., Smith, C. I. E., & Cybulsky, M. I. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.1.288 · Cited by 151
Ponader, S., & Burger, J. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.1046 · Cited by 132
Tam, C. S. L., Grigg, A., Opat, S., Ku, M., Gilbertson, M., Anderson, M. A., Seymour, J. F., Ritchie, D. S., DiCorleto, C., Dimovski, B., et al. (2015) · Blood · doi:10.1182/blood.v126.23.832.832 · Cited by 111
Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis
Whang, J. A., & Chang, B. Y. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.03.028 · Cited by 97
Chemical genetic strategy for targeting protein kinases based on covalent complementarity
Garske, A. L., Peters, U., Cortesi, A. T., Perez, J. L., & Shokat, K. M. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1111239108 · Cited by 90
Differential Regulation of Human NK Cell-Mediated Cytotoxicity by the Tyrosine Kinase Itk
Khurana, D., Arneson, L. N., Schoon, R. A., Dick, C. J., & Leibson, P. J. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.6.3575 · Cited by 89
Brown, J. R., Harb, W. A., Hill, B. T., Gabrilove, J. L., Sharman, J. P., Schreeder, M. T., Barr, P. M., Foran, J. M., Miller, T., Burger, J. A., et al. (2016) · Haematologica · doi:10.3324/haematol.2015.140806 · Cited by 81
Gómez‐Rodríguez, J., Kraus, Z., & Schwartzberg, P. L. (2011) · FEBS Journal · doi:10.1111/j.1742-4658.2011.08072.x · Cited by 80
Zapf, C. W., Gerstenberger, B. S., Li, X., Limburg, D. C., Anderson, D. R., Caspers, N. L., Han, S., AULABAUGH, A. E., Kurumbail, R. G., Shakya, S., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm301190s · Cited by 76
Park, J. K., Byun, J., Park, J. A., Kim, Y.-Y., Lee, Y. J., Oh, J. I., Jang, S. Y., Kim, Y., Song, Y. W., Son, J., et al. (2016) · Arthritis Research & Therapy · doi:10.1186/s13075-016-0988-z · Cited by 71
Distinct and overlapping functional roles of Src family kinases in mouse platelets
Séverin, S., Nash, C. A., Mori, J., Zhao, Y., Abram, C. L., Lowell, C. A., Senis, Y. A., & Watson, S. P. (2012) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2012.04814.x · Cited by 65
Tec family kinases: regulation of FcεRI‐mediated mast‐cell activation
Ellmeier, W., Abramova, A., & Schebesta, A. (2011) · FEBS Journal · doi:10.1111/j.1742-4658.2011.08073.x · Cited by 52
Btk inhibition treats TLR7/IFN driven murine lupus
Bender, A. T., Pereira, A., Fu, K., Samy, E. T., Wu, Y., Liu‐Bujalski, L., Caldwell, R. D., Chen, Y.-Y., Tian, H., Morandi, F., et al. (2016) · Clinical Immunology · doi:10.1016/j.clim.2016.01.012 · Cited by 52
Investigational Bruton’s tyrosine kinase inhibitors for the treatment of rheumatoid arthritis
Norman, P. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2016.1182499 · Cited by 50
FOXO1 repression contributes to block of plasma cell differentiation in classical Hodgkin lymphoma
Vogel, M. J., Xie, L., Guan, H., Tooze, R. M., Maier, T. H. P., Kostezka, U., Maier, H. J., Holzmann, K., Chan, F. C., Steidl, C., et al. (2014) · Blood · doi:10.1182/blood-2014-07-590570 · Cited by 38
Cited by
Advances in covalent drug discovery
Boike, L., Henning, N. J., & Nomura, D. K. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00542-z · Cited by 823
Byrd, J. C., Hillmen, P., Ghia, P., Kater, A. P., Chanan-Khan, A., Furman, R. R., O'Brien, S., Yenerel, M. N., Illés, A., Kay, N., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01210 · Cited by 669
Self-citationSabe, V. T., Ntombela, T., Jhamba, L. A., Maguire, G. E. M., Govender, T., Naicker, T., & Kruger, H. G. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113705 · Cited by 625
Properties of FDA-approved small molecule protein kinase inhibitors
Roskoski, R. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.03.006 · Cited by 554
Wang, M., Rule, S., Zinzani, P. L., Goy, A., Casasnovas, O., Smith, S. D., Damaj, G., Doorduijn, J., Lamy, T., Morschhauser, F., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33108-2 · Cited by 453
Metadata
- Authors
- Barf, T., Covey, T., Izumi, R., van de Kar, B., Gulrajani, M., van Lith, B., van Hoek, M., de Zwart, E., Mittag, D., Demont, D., Verkaik, S., Krantz, F., Pearson, P. G., Ulrich, R., & Kaptein, A.
- Venue
- The Journal of Pharmacology and Experimental Therapeutics
- Publisher
- Elsevier BV
- Published
- 2017-11
- Volume
- 363
- Issue
- 2
- Pages
- 240-252
- ISSN
- 0022-3565 (ISSN-L)
- OpenAlex
- W2750906538
- Cited by
- 380
- References
- 40
- FWCI
- 15.52
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.